Senju Pharmaceutical has been granted a patent for a composition to treat corneal endothelium symptoms. The method involves administering (T)EW-7197 or its derivatives to prevent or treat corneal endothelial conditions. GlobalData’s report on Senju Pharmaceutical gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Senju Pharmaceutical, Nanoparticle drug conjugates was a key innovation area identified from patents. Senju Pharmaceutical's grant share as of January 2024 was 45%. Grant share is based on the ratio of number of grants to total number of patents.
Composition for treating corneal endothelial conditions
A recently granted patent (Publication Number: US11857544B2) discloses a method for treating or preventing corneal endothelial conditions, disorders, or diseases by administering an effective amount of (T)EW-7197 or its derivatives. The method aims to suppress a reduction in corneal endothelial cell density, particularly targeting conditions such as Fuchs' endothelial corneal dystrophy or corneal guttata. The treatment is designed to address issues related to the overexpression of extracellular matrix (ECM), including types I, IV, and V collagen, as well as fibronectin.
The administration of (T)EW-7197, or its derivatives, at specified concentrations ranging from 0.001 mM to 10 mM, or 0.01 mM to 5 mM, has shown promising results in treating various corneal endothelial conditions. The method involves the use of eye drops for convenient application. The patent highlights the potential of this approach in addressing a range of conditions such as guttae formation, Descemet's membrane thickening, corneal opacity, and blurred vision, offering a novel therapeutic option for individuals suffering from these ailments.
To know more about GlobalData’s detailed insights on Senju Pharmaceutical, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
